SCHEMBL23932132

SCHEMBL23932132

CN(c1ccc2ncc(-c3ccc4nccn4c3)n2n1)C1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FYN P06241 11/20 0.41
MKNK1 Q9BUB5 1/20 0.41
RIPK2 O43353 1/20 0.39
NTRK1 P04629 1/20 0.37
NTRK3 Q16288 1/20 0.37
NTRK2 Q16620 1/20 0.37
PIM1 P11309 2/20 0.37
DYRK1A Q13627 2/20 0.37
NAMPT P43490 1/20 0.36
IKBKB O14920 1/20 0.36
TGFBR1 P36897 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23932159 0.82 FYN (0.47) FYNMKNK1NTRK1NTRK3NTRK2
SCHEMBL23931952 0.77 ERN1 (0.49) FYNRIPK2PIM1IKBKB
SCHEMBL23932050 0.77 FYN (0.56) FYNMKNK1RIPK2PIM1DYRK1A
SCHEMBL23932104 0.77 ERN1 (0.57) FYNRIPK2PIM1DYRK1A
SCHEMBL23931890 0.76 FYN (0.44) FYNMKNK1RIPK2PIM1DYRK1A
SCHEMBL23931845 0.76 FYN (0.42) FYNMKNK1RIPK2PIM1DYRK1A
SCHEMBL25726519 0.76 FYN (0.42) FYNMKNK1RIPK2NTRK1NTRK3
SCHEMBL23932146 0.76 FYN (0.47) FYNMKNK1RIPK2PIM1DYRK1A
SCHEMBL23932231 0.76 FYN (0.42) FYNMKNK1RIPK2PIM1DYRK1A
SCHEMBL25726395 0.76 FYN (0.42) FYNMKNK1RIPK2NTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof THE UAB RESEARCH FOUNDATION (US) 2025-10-07 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
WO-2021216757-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed
WO-2021216757-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF HNRNPR, HNRNPAB, RBM3 FYN 2657/4885MKNK1 1675/4885RIPK2 1665/4885
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof HNRNPR, HNRNPAB, RBM3 FYN 2657/4885MKNK1 1675/4885RIPK2 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.